![]() |
市場調查報告書
商品編碼
2170797
潛伏性結核感染檢測市場:全球市場預測,2026-2032年Latent Tuberculosis Infection Detection Market - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,潛伏性結核感染檢測市場規模將成長至 23.1 億美元,複合年成長率為 6.49%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 14.8億美元 |
| 預計年份:2026年 | 15.8億美元 |
| 預測年份 2032 | 23.1億美元 |
| 複合年成長率 (%) | 6.49% |
潛伏性結核感染(LTBI)的檢測旨在識別已感染結核分枝桿菌但尚未發展為活動性結核病的個體。主要的診斷方法是結核菌素皮膚試驗(TST)和干擾素釋放檢測法(IGRA),必要時輔以臨床評估和活動性結核病的診斷檢測。正確識別的LTBI在結核病預防中發揮核心作用,因為治療可以抑制其發展為活動性結核病,尤其適用於近期接觸過結核病或具有高風險臨床風險的人。
目前的趨勢是從廣泛、低檢出率的篩檢轉向針對已確診暴露人群、近期從高感染地區遷徙而來的人員、免疫功能低下者、有醫療機構或集體生活環境暴露史者以及其他具有已知風險因素的人群進行靶向檢測。雖然在接種卡介苗後結核菌素皮膚試驗(TST)特異性可能降低的情況下,干擾素γ釋放試驗(IGRA)的使用正在增加,但在檢測能力、成本或人力資源有限而難以進行血液檢測的情況下,TST仍然發揮著至關重要的作用。加強檢測、確診和預防性治療之間的協調與選擇初始檢測方法同等重要。
人工智慧 (AI) 可以透過優先確定篩檢目標、識別漏診病例、改進用於排除活動性疾病的影像學檢查觀察的解讀以及協助醫療系統內檢測能力的分配來支持潛伏性結核感染 (LTBI) 計畫。其價值取決於具有代表性的訓練資料、透明的檢驗、隱私保護以及與臨床工作流程的整合。人工智慧本身無法確診 LTBI;演算法輸出結果除了需要微生物學、放射學和流行病學證據外,還需要合格專業人員的臨床審查。
在北美,篩檢通常著重於密切接觸者、來自高發生率地區的移民、接受免疫抑制治療的人群以及特定職業群。在拉丁美洲,家庭密切接觸者追蹤與改善檢測和預防性治療的可近性相結合。在歐洲,流行病學情況因國家而異,移民、密切接觸者和弱勢群體仍然是優先考慮的對象。在中東和非洲,需要加強密切接觸者追蹤、愛滋病毒和免疫抑制服務以及基層醫療的整合。在亞太地區,既存在高發生地區,也存在低發病率的先進項目,因此分散式服務取得、品質保證和基於風險的篩檢尤為重要。
東協成員國可受益於在不同的醫療保健系統、移民健康和檢查室品管方面採用可互通的方法進行接觸者追蹤。金磚國家有機會協調在龐大且多元化的人群中進行調查、獲取診斷和累積實施經驗。歐盟可以加強通用指南、跨境衛生連續性和監測互通性。七國集團成員國可以支持證據產生、加強檢測系統和確保公平取得。海灣合作理事會國家可以專注於高流動性勞動力和移民的篩檢和衛生連續性,而北約成員國可以加強軍事相關人員和作戰人員的準備工作和標準化方法。
澳洲、加拿大、法國、德國、義大利、英國、英國和美國通常依賴基於風險的策略,以接觸者追蹤、為移民和難民提供醫療保健服務以及在開始某些免疫抑制療法之前篩檢基礎。巴西、印度、中國、印尼、墨西哥、俄羅斯和韓國必須在滿足其巨大的結核病控制需求的同時,兼顧檢測的可及性、卡介苗接種的普及以及區域差異。日本將成熟的公共衛生基礎設施與針對接觸者和臨床易感族群的篩檢結合。在上述所有國家,最有效的途徑是將結核菌素皮膚試驗(TST)或γ-干擾素釋放試驗(IGRA)陽性結果與及時排除活動性結核病、制定預防性治療方案、支持患者堅持用藥以及監測治療效果聯繫起來。
領導者應優先考慮準確且易於取得的檢測,並設計涵蓋整個診療流程的服務,而不僅僅是檢測數量。這包括明確的基於風險的合格標準、可靠的檢體運輸、內部品管、快速的結果溝通、臨床決策支援以及轉診途徑。與公共衛生計畫合作可以改善接觸者追蹤,並擴大對服務不足人口的支持。各機構還應衡量無效或不確定檢測結果、臨床評估所需時間、預防保健的啟動和完成情況、獲取服務的公平性以及安全性結果。只有在有證據表明存在管治、人工監督以及在目標人群中已證實有效的績效時,才能實施數位工具和人工智慧。
本執行摘要整合了用於檢測潛伏性結核感染 (LTBI) 的既定臨床和公共衛生原則,包括結核菌素皮膚試驗 (TST) 和干擾素γ釋放試驗 (IGRA) 的作用、基於風險的篩檢、排除活動性結核病、接觸者追蹤以及預防保健的協調。區域分析從所要求的區域、群體和國家觀點闡述了實施重點,而未賦予具體的市場價值。結論是基於已證實的流行病學和醫療保健系統差異,避免了未經證實的估計值、預測、公司歸因或市場佔有率聲明。
潛伏性結核感染(LTBI)的檢測在以下情況下最為有效:針對高風險族群進行檢測,結合臨床情況解讀檢測結果,並迅速與活動性結核病的評估和預防性治療相結合。儘管由於地區和國家差異,單一的運作模式並不適用,但通用的優先事項依然存在:可靠的診斷、訓練有素的工作人員、公平的獲取途徑、高品質的數據以及持續的追蹤。人工智慧(AI)有助於改善協調和優先排序,但負責任的實施需要檢驗和臨床課責。最佳方案會將檢測置於結核病綜合預防流程中不可或缺的一部分。
The Latent Tuberculosis Infection Detection Market is projected to grow by USD 2.31 billion at a CAGR of 6.49% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.48 billion |
| Estimated Year [2026] | USD 1.58 billion |
| Forecast Year [2032] | USD 2.31 billion |
| CAGR (%) | 6.49% |
Latent tuberculosis infection (LTBI) detection identifies people infected with Mycobacterium tuberculosis who do not have active tuberculosis disease. The principal tools are tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs), supported by clinical assessment and evaluation for active disease when indicated. Detection is central to tuberculosis prevention because treatment of appropriately identified LTBI can reduce progression to active disease, particularly among people with recent exposure or elevated clinical risk.
The landscape is moving from broad, low-yield screening toward targeted testing of people with documented exposure, recent migration from high-transmission settings, immunosuppression, healthcare or congregate-setting exposure, and other recognized risk factors. IGRAs are increasingly used where BCG vaccination may reduce the specificity of TST, while TST remains important where laboratory infrastructure, cost, or workforce capacity constrain blood-based testing. Better linkage between testing, confirmatory evaluation, and preventive treatment is becoming as important as the initial test choice.
Artificial intelligence can support LTBI programs by prioritizing people for screening, identifying missed follow-up, improving interpretation of radiographic findings used to exclude active disease, and helping health systems allocate testing capacity. Its value depends on representative training data, transparent validation, privacy safeguards, and integration with clinical workflows. AI cannot by itself establish LTBI, and algorithmic outputs require qualified clinical review alongside microbiological, radiological, and epidemiological evidence.
North America generally emphasizes targeted screening among contacts, immigrants from high-burden settings, people receiving immunosuppressive therapies, and selected occupational groups. Latin America combines household-contact investigation with efforts to improve access to testing and preventive treatment. Europe faces varied epidemiology across countries and continues to prioritize migrants, contacts, and vulnerable populations. The Middle East and Africa require stronger integration of contact investigation, HIV and immunosuppression services, and primary care. Asia-Pacific contains both high-burden settings and advanced low-incidence programs, making decentralized access, quality assurance, and risk-based screening especially important.
ASEAN members can benefit from interoperable approaches to contact tracing, migrant health, and laboratory quality across diverse health systems. BRICS countries have an opportunity to coordinate research, diagnostics access, and implementation experience across large and varied populations. The European Union can reinforce common guidance, cross-border continuity of care, and surveillance interoperability. G7 members can support evidence generation, laboratory strengthening, and equitable access. GCC countries can focus on screening and continuity of care for mobile workforces and migrants, while NATO members can strengthen preparedness and standardized approaches for military and operational populations.
Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States generally rely on risk-based strategies supported by contact investigations, immigrant and refugee health services, and screening before selected immunosuppressive treatments. Brazil, India, China, Indonesia, Mexico, Russia, and South Korea must balance substantial tuberculosis-control needs with differing laboratory access, BCG practices, and regional variation. Japan combines mature public-health infrastructure with targeted screening of contacts and clinically vulnerable groups. Across all listed countries, the most effective pathway connects a positive TST or IGRA with timely exclusion of active disease, preventive-treatment decisions, adherence support, and outcome monitoring.
Leaders should prioritize accurate, accessible tests and design services around the full cascade of care rather than test volume alone. This includes clear risk-based eligibility criteria, dependable specimen transport, internal quality controls, rapid result communication, clinical decision support, and referral pathways for preventive treatment. Partnerships with public-health programs can improve contact investigation and reach underserved populations. Organizations should also measure invalid or indeterminate results, time to clinical evaluation, preventive-treatment initiation and completion, equity of access, and safety outcomes. Digital tools and AI should be deployed only with governance, human oversight, and evidence of performance in the populations served.
This executive summary synthesizes established clinical and public-health principles for LTBI detection, including the roles of TST and IGRA, risk-based screening, exclusion of active tuberculosis, contact investigation, and preventive-treatment linkage. The geographic analysis uses the requested regional, group, and country lenses to describe implementation priorities without assigning numerical market values. Conclusions are framed around documented epidemiological and health-system differences, while avoiding unsupported estimates, forecasts, company attribution, or market-share claims.
LTBI detection is most effective when testing is targeted to meaningful risk, interpreted in clinical context, and connected rapidly to active-disease evaluation and preventive treatment. Regional and country differences make a single operational model unsuitable, but common priorities remain: reliable diagnostics, trained staff, equitable access, high-quality data, and sustained follow-up. Artificial intelligence may improve coordination and prioritization, yet responsible implementation requires validation and clinical accountability. The strongest programs will treat detection as one component of an integrated tuberculosis-prevention pathway.